Cannabis

Healio and Cardiology Today compiled the most-read cardiology news of February 2022.

As the use of cannabis products becomes more frequent for dermatologic conditions, clinicians should be aware of barriers and stay up to date with both the science and legal sides of its use, according to a study.

Habitual cannabis use was associated with greater risk for recurrent stroke among younger adults with a history of stroke or transient ischemic attack vs. nonuse, according to data presented at the International Stroke Conference.

As cannabis use grows with expanded legalization, a group of experts is investigating allergic reactions to cannabis and developing potential policy and treatment to improve care, according to a review published in Allergy.

Examination of positive urine drug screens of teenagers was not a reliable predictor for risk for death by external causes, according to a population-based retrospective cohort study published in the Journal of Clinical Psychiatry.

Impaired driving performance after smoking cannabis appeared to resolve within 4 hours, 30 minutes in most individuals, according to a double-blind, placebo-controlled parallel randomized clinical trial in JAMA Psychiatry.

In Canada, pediatric ED visits due to cannabis exposure significantly increased after recreational cannabis was legalized, according to recent data.

Among patients with aneurysmal subarachnoid hemorrhage, those with recent cannabis use were more likely to have delayed cerebral ischemia than those without recent use, researchers reported.

In last week’s top story in cardiology, a cross-sectional analysis found that cannabis use was significantly associated with increased odds of having a high atherosclerotic CVD risk.

Elevated atherosclerotic CVD risk was linked to cannabis use in a study published in the American Journal of Cardiology.